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ABSTRACT
Background: The current TNM staging system for oesophageal adenocarcinoma 
(OAC) has limited ability to stratify patients and inform clinical management following 
neo-adjuvant chemotherapy and surgery.
Results: Functional genomic analysis of the gene expression data using Gene Set 
Enrichment Analysis (GSEA) identified GLUT1 as putative prognostic marker in OAC.
In the discovery cohort GLUT1 positivity was observed in 114 patients (80.9%) 
and was associated with poor overall survival (HR 2.08, 95% CI 1.1-3.94; p=0.024) 
following multivariate analysis. A prognostic model incorporating GLUT1, CRM and 
nodal status stratified patients into good, intermediate and poor prognosis groups 
(p< 0.001) with a median overall survival of 16.6 months in the poorest group.
In the validation set 182 patients (69.5%) were GLUT1 positive and the 
prognostic model separated patients treated with neo-adjuvant chemotherapy and 
surgery (p<0.001) and surgery alone (p<0.001) into three prognostic groups.
Patients and Methods: Transcriptional profiling of 60 formalin fixed paraffin-
embedded (FFPE) biopsies was performed. GLUT1 immunohistochemical staining was 
assessed in a discovery cohort of 141 FFPE OAC samples treated with neo-adjuvant 
chemotherapy and surgery at the Northern Ireland Cancer Centre from 2004-2012. 
Validation was performed in 262 oesophageal adenocarcinomas collected at four 
OCCAMS consortium centres. The relationship between GLUT1 staining, T stage, N 
stage, lymphovascular invasion and circumferential resection margin (CRM) status 
was assessed and a prognostic model developed using Cox Proportional Hazards.
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Conclusions: GLUT1 staining combined with CRM and nodal status identifies a 
poor prognosis sub-group of OAC patients and is a novel prognostic marker following 
potentially curative surgical resection.
INTRODUCTION
In Western populations the incidence of oesophageal 
adenocarcinoma (OAC) in men has risen by 6-fold in the 
last 30 years and has become the dominant histological 
subtype [1, 2]. The addition of neo-adjuvant therapy prior 
to surgical resection has improved survival for localised 
disease but there are wide variations in outcomes [3, 4].
The prediction of prognosis after potentially 
curative surgery is currently based on the internationally 
accepted TNM classification system but its limited 
ability to stratify patients has led to the investigation of 
additional biomarkers. Pathological features, such as 
nodal involvement, lymphovascular invasion (LVI) and 
circumferential resection margin (CRM) status, provide 
additional prognostic information and in cases treated 
with neo-adjuvant chemotherapy a histopathological 
response in the tumour or lymph nodes has been shown 
to predict improved survival [5–7]. However, a recent 
analysis of the Medical Research Council Gastric 
Infusional Chemotherapy (MAGIC) trial demonstrated 
that positive lymph node status and not pathological 
response was the only independent predictor of survival, 
albeit in a predominantly gastric adenocarcinoma sample 
set (76%) [8]. The use of 2-[18F]fluoro-2-deoxy-D-
glucose (FDG) positron emission tomography (PET) to 
predict benefit to chemotherapy and prognosis has also 
been investigated with OACs displaying persistently high 
levels of FDG uptake, even after the administration of 
chemotherapy, associated with higher rates of relapse and 
poor survival [9, 10]. Current prognostic strategies do not 
take into account the molecular features of each tumour 
which may explain the wide variation in survival amongst 
patients with similar metabolic and pathological staging. 
Robust prognostic biomarkers are required to enable the 
stratification of OAC patients following surgical resection.
Recently, comprehensive whole genome sequencing 
and multiple platform analyses have led to the discovery 
of novel molecular sub-groups in OAC and may improve 
prognostication [11–14]. At present the application of 
next-generation sequencing techniques has not extended to 
routine use in pathology laboratories and so there remains 
a role for immunohistochemical (IHC) biomarkers. A wide 
range of IHC prognostic markers have been investigated 
in OAC, including the development and validation of a 
three gene prognostic panel of Epidermal Growth Factor 
(EGFR), Tripartite Motif-containing 44 (TRIM44) and 
Sirtuin 2 (SIRT2), but to date none have entered routine 
clinical practice [15–17]. Markers may be discovered 
through an understanding of the molecular biology of 
OAC, by analysis of genomic data or from being identified 
as a prognostic marker in other tumour types. Once 
identified the studies for each marker are often limited 
by a small number of cases, absence of a defined scoring 
methodology and lack of validation in an independent 
dataset.
In the current study we, therefore, aimed to identify 
robust IHC prognostic markers which could be used to 
inform the management of OAC using FFPE material. 
Specifically, we focused on the identification of potential 
biomarkers from transcriptional data followed by 
development and validation of an IHC marker. Unlike 
previous studies, we examined the interaction of our 
biomarkers with pathological features and have developed 
a prognostic model which could be used in post-
chemotherapy resection material to inform post-operative 
surveillance or treatment strategies.
RESULTS
Gene expression and gene set enrichment 
analysis (GSEA)
Functional analysis of gene expression data from 
60 FFPE OAC biopsies (Supplementary Table 1) was 
performed to generate a list of candidate prognostic 
biomarkers. Cases were divided into pathological 
responders (TRG ≤2, n=7) and non-responders (TRG 
3-5, n=53) and GSEA using the C2 canonical pathways 
gene set database identified ten pathways associated with 
pathological response to neo-adjuvant chemotherapy 
(Supplementary Table 2). The top-ranked pathway was the 
Hypoxia-inducible factor 1 (HIF1) pathway and a ranked 
gene list of HIF1 pathway genes, beginning with the 
most upregulated gene in the non-responders compared 
to the responders was generated (Supplementary Figure 
1, Supplementary Table 3). The enriched genes from 
this pathway contained a number of genes implicated as 
prognostic markers in oesophageal and other cancers, such 
as Insulin-like Growth Factor Binding Protein 1 (IGFBP1), 
N-myc Downstream Regulated Gene 1 (NDRG1), Trefoil 
Factor 3 (TFF3) and Solute Carrier Family 2 Member 1/
Glucose Transporter 1 (SLC2A1).
Candidate gene selection
To select a candidate biomarker from the 
HIF1 pathway an MA plot of gene expression levels 
corresponding to the HIF1 pathway was performed 
and a False Discovery Rate (FDR) of <0.1 applied 
(Supplementary Figure 2). We further assessed the list of 
candidates according to the published literature for genes 
with a biological role in oesophageal cancer, potential as 
a prognostic marker and for availability of a validated 
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antibody. Four candidates were selected (SLC2A1, 
IGFBP1, NDRG1, TFF3) of which SLC2A1 was the 
only gene to have FDR <0.1 and expression of SLC2A1 
was strongly correlated with both IGFBP1 and NDRG1 
(Spearman’s correlation co-efficient; FDR <0.1) indicating 
its expression was representative of these HIF1 pathway 
candidates. SLC2A1 encodes the membrane protein 
Glucose Transporter 1 (GLUT1) and high expression 
of GLUT1 has been associated with poor survival in 
oesophageal squamous cell carcinoma and progression of 
Barrett’s oesophagus to adenocarcinoma but GLUT1 has 
not been studied as a prognostic marker in OAC [18–23]. 
The primary mechanism for the accumulation of FDG 
in cancer cells during PET scans is through GLUT1-
mediated transport and so the persistently high levels of 
FDG uptake associated with a poor prognosis in OAC 
may be mediated by high GLUT1 expression [24, 25]. 
Considering the prognostic ability of GLUT1 in a range of 
tumour types, its role in PET response and the availability 
of a robust and validated antibody we selected GLUT1 for 
further investigation as a prognostic marker in OAC.
GLUT1 immunohistochemistry
Expression of GLUT1 was observed in the 
cytoplasm and at the cell membrane of OAC cells and 
heterogeneous staining was noted. (Supplementary Figure 
3) [24]. GLUT1 expression was assessed in a discovery set 
consisting of resection specimens from 141 oesophageal 
and gastro-oesophageal junction adenocarcinoma patients 
(Table 1) and no GLUT1 staining was observed in 27 
cases (19.1%) with weak, moderate and strong staining 
observed in 49 (34.8%), 37 (26.2%) and 29 (20.6%) cases 
respectively (Figure 1). Close agreement was observed 
between three independent pathologists (Concordance 
correlation coefficient= 0.88; 95% CI 0.83-0.91). No 
significant association was found between GLUT1 and 
expression of the clinically validated markers Her2, p53 
or MET (Supplementary Table 4).
To increase the clinical utility of GLUT1 as 
a biomarker, and to enable a more reliable scoring 
methodology, we defined GLUT1 positivity as any cancer 
cells staining for GLUT1, regardless of the intensity 
or percentage of cells. With the exception of tumour 
differentiation, there were no significant differences in 
any major clinicopathological factors between GLUT1 
negative and positive patients (Supplementary Table 5).
The relationship between GLUT1 expression, four 
known pathological factors (LVI, CRM, differentiation 
and nodal status) and prognosis were examined further 
by univariate (Supplementary Table 6) and multivariate 
analysis (Table 2). In univariate analysis GLUT1 positivity 
was a significant predictor of reduced relapse-free survival 
(RFS) (HR 2.07, 95% CI 1.09-3.93; p=0.026) with a 
median RFS of 21.2 (95% CI 15.9-29.2) and 63.7 (95%CI 
28.1-NA) months for GLUT1 positive and negative 
patients respectively (Supplementary Figure 4A). Overall 
survival (OS) was also significantly reduced for GLUT1 
positive patients (HR 1.85, 95% CI 1.01-3.39; p=0.047) 
with a median OS of 31.6 (95%CI 23.4-38.4) months 
in GLUT1 positive patients and 43.9 (95%CI 32.7-NA) 
months in GLUT1 negative cases (Supplementary Figure 
4B). Following multivariate analysis GLUT1 positivity 
remained an independent prognostic factor alongside 
CRM and nodal status in this cohort uniformly treated 
with neo-adjuvant chemotherapy and surgical resection 
Figure 1: Tissue Microarray GLUT1 staining.  Representative 10X and 40X views of tumours showing negativity for GLUT1 (A) 
and weak (B), moderate (C) and strong (D) staining for GLUT1.
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Table 1: Comparison of discovery and validation tissue microarrays
Discovery TMA NICC Validation TMA OCCAMS p-value
n = 141 (%) n = 262 (%)
Age
 <60 42 (30) 80 (31) 0.034
 60-69 67 (47) 92 (35)
 ≥ 70 32 (24) 86 (33)
 Unknown 0 4 (2)
 Median 63 66 0.058†
 Range 28-83 33-88
Sex
 Male 110 (78) 213 (81) 0.431
 Female 31 (22) 49 (19)
 Unknown 0 6 (2)
Tumour Site
 Oesophagus 22 (17) 262 (100) NA
 GOJ, Siewert 1 72 (52)
 GOJ, Siewert 2 35 (23)
 GOJ, Siewert 3 12 (8)
Depth of Invasion (T stage)
 pT0/1 15 (11) 21 (8) 0.578
 pT2 27 (19) 56 (21)
 pT3 94 (67) 180 (69)
 pT4 5 (4) 5 (2)
Lymph node Involvement (N stage)
 N0 51 (36) 72 (27) 0.008
 N1 29 (21) 92 (35)
 N2/3 61 (43) 96 (37)
 Unknown 0 2 (1)
Differentiation
 Well 6 (4) 21 (8) 0.189
 Moderate 53 (38) 79 (30)
 Poor 81 (57) 151 (58)
 Unknown 1 (1) 11 (4)
Lymphovascular Invasion
 Negative 47 (33) 98 (37) 0.004
 Positive 93 (66) 101 (39)
 Unknown 1 (1) 63 (24)
(Continued )
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(Table 2). Variables were selected using the elastic 
net penalty method (Supplementary Table 7) and the 
concordance index to assess the predictive fit of each 
model (Supplementary Table 8). The relative contribution 
of each variable was also assessed by the log likelihood 
ratio, with the greatest effect observed for nodal status 
(Supplementary Table 9).
Probability nomograms for RFS and OS 
(Supplementary Figure 5 and Table 2) combining 
GLUT1, CRM and nodal status were derived from 
the respective multivariate Cox regression models. 
Prognostic indices for OS and RFS were developed from 
the respective nomograms, based on combinations of 
GLUT1, CRM and nodal status. Each prognostic index 
was used to separate patients into three groups - good, 
intermediate and poor prognosis (Table 3). The poor 
prognosis group was associated with an RFS and OS 
of 13 and 16.6 months respectively following surgical 
resection (Figure 2).
Validation cohort
The validation set consisted of 262 OAC patients 
of whom 127 (69.8%) were treated with neo-adjuvant 
Discovery TMA NICC Validation TMA OCCAMS p-value
n = 141 (%) n = 262 (%)
Circumferential Margin Involvement
 Negative 77 (55) 113 (43)
0.073 Positive 63 (45) 61 (23)
 Unknown 1 (1) 88 (34)
Neo-Adjuvant chemotherapy
 Yes 141 (100) 127 (48)
<0.0001
 No 0 135 (52)
†Mann-Whitney U Test
NICC- Northern Ireland Cancer Centre
OCCAMS- Oesophageal Cancer Clinical and Molecular Stratification Consortium.
Table 2: Multivariate analysis of clinicopathological factors, GLUT1 expression, relapse-free and overall survival in 
the discovery cohort
Relapse-free Survival Overall Survival
Hazard Ratio 95% CI p-value Hazard Ratio 95% CI p -value
CRM
 Negative 1 1
 Positive 2.059 1.167-3.631 0.01 1.897 1.067-3.373 0.03
N Stage
 0 1 1
 1 1.542 0.749-3.176 0.24 2.189 0.999-4.796 0.05
 2/3 3.962 2.017-7.782 <0.001 5.694 2.742-11.823 <0.001
Differentiation
 Poor 1 1
 Moderate 1.19 0.717-1.967 0.502 1.05 0.194-3.703 0.827
 Well 0.862 0.198-3.763 0.844 0.849 0.624-1.764 0.855
GLUT1
 Low 1 1
 High 2.352 1.191-4.647 0.014 2.059 1.08-3.922 0.028
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chemotherapy followed by surgery and 135 (74.2%) by 
surgery alone (Table 1, Supplementary Table 10). Patients 
in the validation set were older, had a significantly higher 
nodal status and a lower proportion of cases were LVI 
positive. GLUT1 expression did not show a significant 
correlation with any pathological factor but higher GLUT1 
positivity was observed in chemotherapy-naïve patients 
(Supplementary Table 11). GLUT1 positive patients had 
a significantly worse prognosis (HR 1.85, 95% CI 1.11-
3.08, p = 0.018) with a median OS of 18 (95% CI 17-
24) and 39 (95% CI 33-53) months in GLUT1 positive 
and negative patients respectively (Supplementary 
Figure 6). GLUT1 was confirmed as a statistically 
significant prognostic indicator of worse OS in both the 
univariate and multivariate analysis for the neo-adjuvant 
chemotherapy and surgery treated patients but did not 
retain significance in the multivariate analysis for the 
chemotherapy-naïve patients (Supplementary Table 12). 
However, the prognostic model developed in the NICC 
cohort successfully stratified patients into three prognostic 
groups regardless of whether the patient received neo-
adjuvant chemotherapy or not (p<0.001) (Figure 3, 
Supplementary Table 13).
These results confirm the ability of our prognostic 
score incorporating GLUT1, CRM and nodal status 
to stratify patients following oesophagectomy and, in 
particular, to identify a poor prognosis group of patients.
DISCUSSION
In this study we have performed biomarker selection 
using gene expression data and identified GLUT1 as an 
immunohistochemical marker. We have developed a 
prognostic model incorporating GLUT1 expression, 
Table 3: Prognostic model incorporating N stage, CRM and GLUT1 in the discovery cohort
Prognostic 
Group
Variable Combination Median RFS (95% CI 
months)
Median OS (95% CI 
months)N Stage GLUT1/CRM Status
Group 1 N Stage 0 GLUT1 Negative AND CRM 
Negative
Not reached Not reached
N Stage 1
Group 2 N Stage 2/3 GLUT1 Negative AND CRM 
Negative
39 (21.2-NA) 39.2 (34.5-NA)
N Stage 0 GLUT1 Positive AND CRM 
Positive
N Stage 1 GLUT1 Positive OR CRM 
Positive
Group 3 N Stage 1 GLUT1 Positive AND CRM 
Positive
13 (9.9-15.9) 16.6 (11.7-20.9)
N Stage 2/3 GLUT1 Positive AND/OR CRM 
Positive
Figure 2: Kaplan-Meier plots of relapse-free (A) and overall survival (B) for the prognostic score in the discovery set.
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CRM and nodal status which stratifies patients into three 
prognostic groups when applied to OAC resection material 
in two independent cohorts.
It has long been recognized that the upregulation of 
glycolysis, known as the Warburg effect, is a characteristic 
feature of cancer cells [26]. Intra-tumoural hypoxia leads 
to increased glycolytic enzyme activity in many cancer 
types and in response cancer cells upregulate GLUT1, 
under the control of HIF-1α [26, 27]. The presence of a 
high degree of intra-tumoural hypoxia has been correlated 
with invasion and metastases of malignant tumours and 
may promote refractoriness to anti-cancer therapies [28–
30]. The heterogeneous staining of GLUT1 observed in 
our study is in keeping with evidence suggesting that 
GLUT1 is expressed primarily in hypoxic areas of the 
tumour [31].
Strengths of our study include the definition 
of GLUT1 positivity as any tumour cells staining for 
GLUT1, increasing the clinical applicability of the assay. 
The development of a prognostic model increased the 
ability to stratify patients compared to GLUT1 status 
alone and validation in an independent sample set was a 
further strength. Due to the greater age of the samples, a 
proportion of patients in the validation set did not receive 
neo-adjuvant chemotherapy and this may account for the 
differing levels of GLUT1 positivity in the discovery 
(80.9%) and validation (69.5%) sets as chemo-sensitive 
tumours which demonstrated a pathological response will 
not be represented on the discovery TMA. The finding 
of a significantly lower proportion of N stage 0 patients 
in the validation cohort may also reflect insufficient 
pre-operative staging prior to the introduction of PET 
scans and the reduced administration of neo-adjuvant 
chemotherapy. In keeping with its discovery in a neo-
adjuvant chemotherapy treated cohort, GLUT1 expression 
predicted survival in the validation set in the context of 
neo-adjuvant chemotherapy and surgery but not with 
surgery alone. However, the prognostic model successfully 
stratified patients in both settings indicating its robustness.
Limitations of our study included the use of pre-
chemotherapy biopsy material for the discovery of 
candidate biomarkers by gene expression analysis followed 
by the investigation of their protein expression in post-
chemotherapy resection material. It was not possible to 
examine the expression of GLUT1 in the biopsies due to the 
limited amount of tumour tissue available and the assessment 
of markers of poor prognosis in post-chemotherapy tissue 
is consistent with current data indicating the persistence of 
oncogenic drivers which contribute to prognosis throughout 
neo-adjuvant chemotherapy [32]. Therefore, we surmised that 
a dominant marker in a poor prognosis subgroup would be 
consistently detected in biopsy material and residual tumour 
tissue which did not respond to chemotherapy.
Our work establishes a role for GLUT1 in more 
accurate prognostication for patients and clinicians. When 
combined with nodal status and CRM into a prognostic 
model GLUT1 contributes to the separation of patients 
into three prognostic groups. The poorest prognostic 
group has a median OS of 16.6 (95% CI 11.7-20.9) and 
20 (95% CI 18-26) months in the discovery and validation 
sets respectively, calling into question the validity of 
treating these patients with the high morbidity approach 
of neo-adjuvant chemotherapy and surgery. It is tempting 
to suggest that patients identified as having a higher 
risk of recurrence should be selected for more intensive 
follow-up or receive alternative post-operative treatment. 
Whilst intensive surveillance regimes have been shown to 
detect cases of local recurrence following radical chemo-
radiotherapy suitable for salvage oesophagectomy the role 
of such follow-up strategies following surgical resection 
for OAC remains controversial [33]. Considering its role 
in tumour progression and resistance to therapy, GLUT1, 
and intra-tumoural hypoxia in general, may also represent 
a potential adjuvant therapeutic target [34].
Figure 3: Kaplan-Meier plots of overall survival for the prognostic score in patients treated with neo-adjuvant chemotherapy and surgery 
(A) and those treated with surgery alone (B) in the validation set.
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In conclusion we have identified GLUT1 
expression as a potential biomarker for poor prognosis 
in resected OAC. We have established a promising assay 
incorporating IHC and pathological factors which is 
informative for patient care following chemotherapy and 
surgical resection.
PATIENTS AND METHODS
This study was performed and reported in line with 
the REMARK recommendations (Supplementary Figure 7 
and Supplementary Table 14) [35, 36].
Gene expression profiling from FFPE tissue
Transcriptional profiling of sixty pre-treatment 
endoscopic OAC FFPE biopsies from patients treated 
with neo-adjuvant chemotherapy followed by surgical 
resection at the Northern Ireland Cancer Centre (NICC) 
from 2004-2010 was performed. (Supplementary Table 1). 
A Mandard score of ≤2 indicated a pathological response 
in the corresponding resection specimen [37]. Total RNA 
was extracted using the Ambion Recoverall Kit (Thermo 
Fisher Scientific, Waltham, MA) and amplified using the 
NuGEN WT-Ovation FFPE System (NuGEN, San Carlos, 
CA). The amplified product was hybridized to the Almac 
Xcel™ Array (Almac, Craigavon, United Kingdom) and 
analysed using the Affymetrix 7G scanner (Affymetrix, 
Santa Clara, CA). Expression data is available at 
ArrayExpress (Accession Number E-MTAB-4666).
Discovery and validation tissue microarrays
The discovery set of 152 FFPE OAC resection 
specimens (matched gene expression data available for 
58 cases) were collected from 2004-2012 at the NICC. 
All patients received neo-adjuvant chemotherapy prior 
to surgical resection and had a median follow up time of 
48.8 months. Pathological staging was defined according 
to International Union Against Cancer (UICC) TNM 
staging, 7th edition. Eight specimens had no tumour tissue 
identifiable and 3 died within 3 months of surgery of 
causes unrelated to their cancer, resulting in 141 cases 
entering the final analysis (Table 1).
Validation was performed using a TMA generated 
from 262 OAC samples from patients who underwent 
potentially curative surgery at one of six Oesophageal 
Cancer Clinical and Molecular Stratification (OCCAMS) 
study group centres (Table 1). The TMAs were constructed 
as previously described [16, 38].
Immunohistochemistry
A 3-μm thick section was deparaffinised and 
endogenous peroxidase activity was quenched with 0.3% 
hydrogen peroxide prior to staining using the Ventana 
Discovery XT® automated immunostainer (Ventana 
Medical Systems Inc, Tuscon, AZ). Antibodies to GLUT1 
(Ventana), c-MET (CONFIRM anti-Total c-MET (SP44), 
Ventana) and Her2 (anti-HER2/neu (4B5), Ventana) were 
used according to the manufacturer’s instructions. Staining 
for p53 was performed as previously described [39]. 
Sections were incubated with GLUT1 antibody at 37ºC for 
8 minutes prior to use of the Omnimap® anti-rabbit HRP 
conjugate detection kit (Ventana). Lung adenocarcinoma 
tissue was used as a positive control and test tissue with no 
primary antibody was used as a negative control.
GLUT1 staining was scored by three independent 
observers (RT, SMcQ & JJ) who were blinded to the 
clinical data. In cases of discordance a consensus score 
was reached after discussion. GLUT1 immunoreactivity 
was considered positive when strong homogeneous 
staining was observed at the cancer cell membrane 
or cytoplasm. Scoring was based on intensity (0 = no 
staining, 1 = weak, 2 = moderate and 3 = strong staining 
observed) with the highest intensity from the three cores 
used for analysis.
Statistical analysis
Microarray data analysis was performed using 
Partek Genomics Suite software, version 6.6 (Partek Inc., 
St Louis, MO). Data was normalized using the Robust 
Microarray Averaging (RMA) method. Statistical analysis 
was performed using R (‘RMS’, ‘HMISC’, ‘COXNET’, 
‘Survival’, ‘epiR’ and ‘powerSurvEpi’ packages). Gene 
Set Enrichment Analysis (GSEA) using the Molecular 
Signature Database (MSigDB v5.0) was performed 
as previously described [40]. Associations between 
GLUT1 status and the clinicopathological characteristics 
were calculated using chi-squared tests, with p-value 
adjustment for multiple comparisons using the Bonferroni 
correction method. Relapse-free and overall survival were 
calculated from the date of surgery to the date of clinical 
or pathological recurrence or death from any cause, 
respectively.
In the discovery cohort, univariate and multivariate 
analyses were performed using Cox proportional hazards 
regression, with hazard ratios and p-values reported. 
Proportional hazards assumptions were tested using 
Schoenfeld residuals. In multivariate Cox proportional 
hazards analysis variable selection was performed using 
a lasso penalty approach with cross-validation [41]. 
The concordance index (c-index) was used to assess the 
predictive fit of each model. Ranging from 0 to 1, a c-index 
of 0.5 suggests a model that is no better than random, 
while a c-index between 0.6 and 0.7 is common in survival 
models. Observed c-indices for each multivariate model 
combination were validated using bootstrap resampling 
validation (n = 150). Nomograms were constructed 
from the Cox proportional hazards models, from which 
prognostic indices were derived. Survival curves were 
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estimated using the Kaplan-Meier method and compared 
using the log-rank test. In the validation cohort, using the 
variables identified in the discovery cohort, a multivariate 
Cox proportional hazards regression analysis (stratified 
by site) was performed and a prognostic index (OS) 
calculated and survival compared as before. Significance 
was set at p = 0.05, unless otherwise stated.
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